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ABSTRACT
RNA polymerase II transcription is associated with
cyclic phosphorylation of the C-terminal domain
(CTD) of the large subunit of RNA polymerase II. To
date, FCP1 is the only speci®c CTD phosphatase,
which is required for general transcription and cell
viability. To identify FCP1-associated proteins, we
constructed a human cell line expressing epitope-
tagged FCP1. In addition to RAP74, a previously
identi®ed FCP1 interacting factor, we determined
that FCP1-af®nity puri®ed extracts contain RNAPII
that has either a hyper- or a hypo-phosphorylated
CTD. In addition, by mass spectrometry of af®nity
puri®ed FCP1-associated factors, we identi®ed a
novel FCP1-interacting protein, named MEP50, a
recently described component of the methylosome
complex that binds to the snRNP's Sm proteins. We
found that FCP1 speci®cally interacts with
components of the spliceosomal U small nuclear
ribonucleoproteins. These results suggest a puta-
tive role of FCP1 CTD-phosphatase in linking the
transcription elongation with the splicing process.
INTRODUCTION
RNA polymerase II is highly conserved among eukaryotes and
it is subjected to reversible phosphorylation during the
transcription cycle. Two forms of RNA PolII exist in vivo,
namely RNA PolIIa and IIo. These two forms differ in the
phosphorylation status of the C-terminal domain (CTD) of the
largest subunit of RNA polymerase. The CTD consists of 27
heptad repeats in yeast and 52 in humans, and dynamic site-
speci®c phosphorylation±dephosphorylation events during the
transcription cycle occur (1). Enzymes that modify the CTD's
phosphorylation state have been identi®ed. Several conserved
cyclin-dependent kinases are capable of phosphorylating
CTD. Srb10/Cdk8 appears to repress transcription by
phosphorylating free RNAPIIo (2±4). Kin28/Cdk7 is a subunit
of TFIIH and it plays an essential role shortly after initiation
(5). Finally, Cdk9, the catalytic subunit of the P-TEFb
complex plays an important role in transcription elongation
both in vivo and in vitro (6).
While several kinases affect the CTD phosphorylation
status during transcription, the FCP1 protein is the only CTD
phosphatase identi®ed thus far (7,8). FCP1 is a conserved
CTD phosphatase that is required for transcription of most
yeast genes and for cell viability (9,10). In addition, it plays a
crucial role in re-cycling RNAPII in vitro (11). FCP1 protein
was originally identi®ed as an interacting protein of RAP74, a
component of the general transcription initiation factor TFIIF,
and it has been found as a component of the PolII holoenzyme.
The FCP1 activity is stimulated by TFIIF and repressed by
TFIIB. Moreover, it has been recently shown that a transcrip-
tion-independent CTD dephosphorylation by FCP1 occurs in
Xenopus laevis indicating that free RNAPII is a natural
substrate for FCP1 activity (12).
A large number of recent observations strongly suggested
that the CTD phosphorylation plays a major role in orches-
trating interaction of the CTD with mRNA processing factors
involved in capping, splicing and polyadenylation (13).
Biochemical and genetic studies strongly suggested that
different modi®ed CTD forms predominate at different stages
of transcription. CTD phosphorylated at Ser5 is localized to
promoters, whereas Ser2 phosphorylation occurs primarily
during elongation (14). In yeast the transition from Ser5 to
Ser2 phosphorylation is regulated by Ctk1 kinase and FCP1
phosphatase, and it has been suggested that FCP1 is implicated
in transcription elongation by modulating the levels of Ser2
phosphorylation (15).
As part of ongoing effort to elucidate the role of FCP1, in
this study we report a biochemical characterization of FCP1
associating factors using an epitope-tagged FCP1 stably
expressing cell line. We found that FCP1-af®nity puri®ed
extracts contain RNAPII and we identi®ed a novel FCP1-
interacting protein, named MEP50, identi®ed as one of three
known components of the methylosome complex involved in
the methylation and assembly of spliceosomal snRNPs Sm
proteins (16). Furthermore, we found that FCP1 speci®cally
*To whom correspondence should be addressed. Tel: +39 081 2535003; Fax: +39 081 2535000; Email: majello@unina.it
Nucleic Acids Research, 2003, Vol. 31, No. 3 999±1005
DOI: 10.1093/nar/gkg197
Nucleic Acids Research, Vol. 31 No. 3 ã Oxford University Press 2003; all rights reserved
interacts with components of the pre-mRNA spliceosomal
snRNPs suggesting a putative role of FCP1 in the recruitment
of pre-mRNA splicing factors during transcription.
MATERIALS AND METHODS
Plasmids
The p3XFLAG-FCP1 construct was obtained by inserting
the R1 fragment from GFP-FCP1 (17) into the p3XFLAG-
CMV-10 (Sigma). To construct the MEP50 expression vector,
the DNA sequences corresponding to the full-length protein
(16) were ampli®ed by PCR from Marathon-Ready HeLa
cDNA (Clontech), and subcloned into the pCMV-MYC vector
(Clontech). The p3XFLAG-PIN1 vector was constructed by
inserting the PIN1 coding sequences into the p3XFLAG-
CMV-10.
Cell culture and transfections
The H1299 cells were cultured in DMEM supplemented with
10% fetal bovine serum. The p3XFLAG-FCP1 was trans-
fected into H1299 cells using the standard calcium phosphate
method, and the cells were cultured for 2 weeks in the
presence of Geneticin (1 mg/ml). Drug-resistant clones were
isolated, and the cell lines expressing FLAG-FCP1 (HFFCP1)
were selected by immunoblotting with anti-FLAG M2
(Sigma). The stably derived cell line was cultured in the
presence of 0.5 mg/ml G418. For transient transfections,
H1299 and HFFCP1 cells (150 cm2 dishes) were transfected
with the same quantities (10 mg) of expression vectors
p3XFLAG-FCP1 and/or pMyc-MEP50 following the standard
calcium phosphate method. Cells were harvested 48 h after
transfections, and nuclear extracts were prepared as described
below. The cell extracts were immunoprecipitated with FLAG
monoclonal antibody (M2) and analyzed by western blotting
using the anti c-Myc as described in the text.
Af®nity puri®cation of FLAG-FCP1
To obtain a large quantity of highly puri®ed FCP1-associated
polypeptides, FCP1 complexes were af®nity puri®ed from
nuclear extracts from 4 3 108 HHFCP1 cells. Cells were
washed in PBS and lysed in buffer A (10 mM HEPES pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT,
0.5 mM PMSF). NP40 to ®nal concentration 0.5% was added
after 15 min on ice. Nuclei were collected by centrifugation
and lysed in buffer C (20 mM HEPES, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and
proteinase inhibitors). Nuclear extracts were collected after
centrifugation of the lysates for 2 h to 25 000 r.p.m. in a
Beckman SW41 rotor at 4°C. Extracts were incubated with
M2 anti-FLAG agarose-conjugated antibody (Sigma) over-
night, followed by extensive washes with BC100 buffer
(100 mM NaCl, 10% glycerol, 20 mM Tris±HCl pH 7.9,
0.1 NP40) and FLAG peptide elution in BC100. The eluted
extracts were TCA precipitated before loading on 5±20%
SDS±PAGE. The gels were treated with colloidal blue staining
kit (Invitrogen). Protein bands were excised from the gel and
destained by repetitive washings with 0.1 M NH4HCO3 pH 7.5
and acetonitrile. Samples were reduced and carboxyamido-
methylated with 10 mM DTT and 55 mM iodoacetamide in
0.1 M NH4HCO3 buffer pH 7.5. Tryptic digestion of the
alkylated samples was performed at 37°C for 18 h using 50 ml
of trypsin 12.5 mg/ml. The resulting peptide mixtures were
directly analyzed on a re¯ectron Voyager DE PRO MALDI-
TOF mass spectrometer (Applied Biosystems). The mass
range was calibrated using the [M+H]+ ion from the standard
peptide mixture provided by the manufacturer. About 1.0 ml of
sample was applied to a sample slide and mixed with 1.0 ml of
a 10 mg/ml a-cyano-4-hydroxycinnamic acid solution in
acetonitrile/0.2% TFA (70:30, v/v) before air-drying. Peptide
mass values recorded in the MALDI spectra were used for
database search using both the Mascot and the MS-Fit
softwares.
Cell fractionation and glycerol gradients centrifugation
Cell fractionation into cytoplasmic and nuclear fractions was
performed as described previously (18). Equal cell volume
from nuclear and cytoplasmic fractions was loaded on the gel.
Nuclear and total extracts were separated on 5±45% glycerol
gradients at 40 000 r.p.m. in an SW41 rotor at 4°C for 15 h as
described (19). Fractions (0.5 ml) were collected and 20 ml of
each fraction was separated by SDS±PAGE and analyzed by
western blotting.
Antibodies
The following antibodies were used for carrying out the
immunological techniques. RAP74 protein was detected using
a mixture of two antisera (C-18 and N-16, Santa Cruz
Biotechnologies). For RNAPII detection the rabbit N-20
(Santa Cruz Biotechnologies) against the N-terminus of the
RNAPII, the mouse monoclonal antibody against the RNAPII
CTD (clone 8WG16; BAbCO Covance), and the speci®c
mouse monoclonal anti-phosphorylated RNAPII CTD-Ser5
and Ser2, H14 and H5 (BAbCO Covance), respectively. The
c-Myc antibody is from Clontech. For spliceosomal subunits
detections the SmB (N-18) and U1 SnRNP 70 (N-20) and
a-tubulin antibody are from Santa Cruz Biotechnologies.
Anti-FLAG M2 af®nity gel is from Sigma. The anti FCP1
antibody was a gift of Dr Reinberg (11). The anti MEP50 was
a gift of Dr Dreyfuss (16). Western blots were processed for
chemiluminescence as described previously (17). For
immuno¯uorescence analysis normal human BJ1 cells
(Clontech) were permeabilized in 0.1% Triton X-100 in
PBS, pre-blocked in 2% BSA-3% NGS in PBS and then
incubated overnight at 4°C with anti-MEP50 diluted 1:200,
followed by incubation with a FITC-coniugated anti-mouse
(Jackson Immunoresearch Lab) secondary antibody (1:400
dilution). Cells were washed, mounted and analyzed by
¯uorescence microscopy. All images were digitally processed
using Adobe Photoshop Software.
Northern blots
Samples were processed and electrophoresed in 8%
SDS±PAGE. RNAs were electro-transferred on Hybond N+
(Amersham). The membranes were cross-linked by UV,
hybridized overnight in hybridization buffer (5 3 SSPE, 5%
Denhardt-s reagent, 0.5% SDS, 50 mg salmon sperm DNA) at
65°C, and washed ®rst for 30 min at 65°C in 1 3 SSC buffer
and twice in 0.2 3 SSC buffer supplemented with 0.1% SDS.
7SK and U1 cDNAs were labeled by nick-translation system
from Invitrogen.
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RESULTS
In vivo interaction between FCP1 and RNAPII
To obtain puri®ed FCP1 complexes we carried out the
isolation of FCP1 complexes from cultured human cells
using the FLAG-tagged method. For this purpose, we
generated a human lung carcinoma cell line H1299 that stably
expressed the FLAG-epitope-tagged FCP1 protein. Several
FLAG-FCP1 stably transfected H1299 clones were obtained
and nuclear extracts were analyzed by western blotting using
FCP1 antibody. Figure 1A shows that different clones exhibit
variable expression of the FLAG-FCP1 protein and the clone
4, expressing lower amount of the exogenous versus the
endogenous FCP1 protein, was chosen for further analysis. We
will refer to this clone as the HFFCP1 cell line. First, we
sought to verify the interaction between the FLAG-tagged
FCP1 and the known partner RAP74. Nuclear cell extracts
were incubated overnight at 4°C with anti-FLAG M2-agarose
beads and, after extensive washing in BC100 buffer, bound
proteins were eluted with the FLAG peptide. In our experi-
mental conditions we found that almost all the FLAG-tagged
FCP1 protein was puri®ed by immunoaf®nity with anti-FLAG
M2-agarose beads (Fig. 1). The eluted FLAG-selected mater-
ial was then analyzed by western blotting with anti-RAP74
antibodies. Figure 1B shows the presence of RAP74, indicat-
ing that the FLAG-FCP1 interacts in vivo with RAP74.
We had previously demonstrated that arti®cial recruitment
of FCP1 to promoter templates, through fusion to a DNA
binding domain (GAL4-DBD), stimulates transcription (17).
Because it was shown that FCP1 is a stoichiometric
component of the human RNAPII holoenzyme complex, a
plausible rationale for the GAL4-FCP1 mediated activation
might involve recruitment of the RNAPII itself. Although
FCP1 phosphatase has a docking site on RNAPII that is
distinct from the CTD (20) a direct binding between FCP1 and
RNAPII has not been clearly proved in cultured mammalian
cells. The association between RNAPII and FCP1 has been
proved recently in Schizosaccaromyces pombe (21).
In order to investigate if human FCP1 interacts in vivo with
RNAPII, FLAG-immunoaf®nity materials from HFFCP1 cell
nuclear extracts were analyzed for the presence of RNAPII by
western blotting using highly speci®c RNAPII antibodies.
As shown in Figure 1B, RNAPII was readily detected using
an antibody (sc-899; N-20) that recognized the N-terminus of
RNAPII. To con®rm and extend these results we used
different RNAPII antibodies that speci®cally recognize the
CTD: the mouse monoclonal 8WG16 recognizes mostly
the hypophosphorylated form, while the H5 and H14
the RNAPII phosphorylated in Ser2 or Ser5, respectively.
We found (Fig. 1B) that all three antibodies revealed the
different unphosphorylated or phosphorylated forms in
FLAG-immunoaf®nity extracts, suggesting that FCP1 can
interact in vivo with the RNAPII independently of the state
(hypo/hyperphosphorylated) and of the site (Ser2/Ser5) of
CTD phosphorylation. The presence of RNAPII in the FLAG-
immunoaf®nity materials was speci®c for FCP1, since FLAG-
af®nity materials derived from a cell line containing an
irrelevant FLAG-fusion protein (H1299 cells expressing a
FLAG-GFP protein) did not show any interaction with
RNAPII (data not shown).
Identi®cation of novel FCP1-associating proteins
To identify new FCP1 cellular partners large amounts of
nuclear extracts from the HFFCP1 cell line were prepared.
Nuclear extracts were separated by af®nity-immunoprecipita-
tion by using an M2 anti-FLAG agarose antibody and bound
proteins were eluted with a FLAG peptide. The af®nity-eluted
extracts were analyzed by SDS±PAGE and coomassie stain-
ing. The results are shown in Figure 2A. By comparison of the
protein pattern with the parental cell line H1299, the FCP1
stable expressing cell line revealed some speci®c bands that
are indicated in Figure 2 relative to their molecular weight.
Western blot analysis by using a RAP74 antibody con®rmed
that the p75 protein corresponds to the RAP74 (data not
shown).
To determine the identity of the other speci®c proteins the
bands were excised from the gel, reduced, alkylated and
Figure 1. (A) Western blotting analysis of FCP1-stably expressing cell clones. Different H1299 cell clones were assayed for FCP1 expression by using an
FCP1-speci®c antibody. Clone 4, expressing lower amount of exogenous versus endogenous FCP1, was chosen for further analysis. The ef®ciency of the
immunoaf®nity of nuclear extracts from cell clone 4 with M2 anti-FLAG beads is shown below (NE, nuclear extract; IP, bound material; PostIP, unbound
material). (B) Nuclear extracts from HFFCP1 cells (NE, nuclear extracts; IP, FLAG-af®nity material) were assayed in western blots using the indicated
antibodies.
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digested with trypsin. The resulting peptide mixtures were
analyzed by mass spectrometry and the recorded mass signals
used for database search. Mass spectrometry data con®rmed
that the p150 band corresponds to the FLAG-FCP1 protein
(data not shown). Of the other speci®c FCP1 coimmunopre-
cipitated proteins here we report the identity of the p40
protein. This protein was found to be a WD repeat protein
termed methylosome protein 50, MEP50. This protein,
together with PRMT5 and pICln, constitutes the 20S
methylosome complex involved in the arginine dimethylation
of the Sm proteins, a crucial step required for in vivo assembly
of snRNP (16).
To con®rm the speci®city of the interaction between FCP1
and MEP50 we cloned by PCR from the Marathon Ready
HeLa cDNA (Clontech) the MEP50 cDNA and constructed a
Myc-tagged MEP50 fusion vector. The H1299 parental cell
line and the HFFCP1 derivative cells were transfected with
the pMyc-MEP50 vector. Nuclear extracts were immunopre-
cipitated with FLAG antibody and tested for MEP50 co-
immunoprecipitation by western blotting using a c-Myc
antibody (Fig. 2C). As reported in Figure 2 the exogenously
expressed MEP50 co-immunoprecipitate with the FCP1
protein. To further validate the interaction between MEP50
and FCP1, the H1299 cells were co-transfected with
p3xFLAG-FCP1 and pMyc-MEP50 vectors, and the inter-
action of the exogenously expressed proteins was shown by
the speci®c co-immunoprecipitation with a FLAG antibody
followed by western blotting with anti-c-Myc. As control,
H1299 cells were co-transfected with pMycMEP50 and an
unrelated FLAG-expressing vector (p3xFLAG-PIN1) (see
Figure 2D). Finally, HFFC1 cell extracts were immuno-
precipitated with FLAG antibody and tested for speci®c
interaction with the endogenous MEP50 protein using a
recently described monoclonal anti-MEP50 antibody (16). As
shown in Figure 2E speci®c interaction was observed only in
the HFFCP1 derivative cell line with respect to the H1299
parental cell line. Collectively, these results strongly indicate
that FCP1 interacts in vivo with MEP50.
The MEP50 protein has been reported as a component of a
cytoplasmic methylosome complex (16), while the FCP1
protein is found exclusively in the nucleus (17). Moreover,
speci®c interaction between the two proteins was detected
using nuclear extracts, thus suggesting that MEP50 might be
present in both nucleus and cytoplasm fractions. To evaluate
the presence of the MEP50 protein in the sub-cellular
compartments, nuclear and cytoplasm extracts of HFFCP1
cells were analyzed by western blot by using the MEP50
antibody (Fig. 3A). As control, the fractionated extracts were
analyzed for the presence of the nuclear FLAG-FCP1 and c-
MYC proteins, and for the exclusively cytoplasmic located a-
tubulin. Although the majority of MEP50 was indeed found in
the cytoplasm, the MEP50 protein was also detected in the
nucleus. The sub-cellular distribution of MEP50 was further
investigated by immuno¯uorescence. As shown in Figure 3B
Figure 2. (A) Identi®cation of FCP1-binding proteins. Coomassie staining of an SDS±PAGE gel containing the FLAG-eluates from the indicated cell nuclear
extracts (see Materials and Methods). (B) MALDI-TOF analysis of af®nity puri®ed MEP50. Monoisotopic peptides corresponding to MEP50 are indicated.
(C) HFFCP1 cells were transfected with the pMyc-MEP50 vector and nuclear extract (NE) and anti-FLAG materials (IP) from untransfected or transfected
HFFCP1 cells were assayed with a c-Myc-speci®c antibody. (D) H1299 cells were co-transfected with the indicated tagged expression vectors and cell
extracts were IP using a FLAG antibody and assayed with the c-Myc antibody. (E) Nuclear extracts from H1299 and HFFCP1 cells (N, nuclear extracts;
IP, FLAG-af®nity material) were assayed in western blot using the MEP50 antibody.
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MEP50 was detected in both nuclear and cytoplasmic
sub-cellular compartments. Thus, biochemical cellular
fractionation and immuno¯uorescence data concordantly
indicated that MEP50 is located in both nucleus and
cytoplasm.
Next, we sought to determine whether FCP1 might be part
of the methylosome complex, or alternatively FCP1 and
MEP50 may belong to a distinct complex. To this end we
carried out glycerol gradient fractionation of H1299 nuclear or
whole-cell extracts and tested the fractions by western blotting
with MEP50 and FCP1 antibodies, respectively. The sedi-
mentation pro®le of whole-cell extract indicated that MEP50
was present in two peaks of ~400 K and >800 K. In sharp
contrast, fractionation of nuclear extract resulted in the
presence of nuclear MEP50 only in the light peak (fractions
5±7). Thus, the sedimentation pro®le of MEP50 is clearly
different from that observed with whole-cell extract.
Interestingly, western analysis of the fractionated nuclear
and whole-cell extracts with anti-FCP1 (Fig. 3C, and data not
shown) indicated that the bulk of phosphatase is present in
fractions 3±5. These results strongly suggest that FCP1 does
not associate with the high molecular complex containing
MEP50. Rather, it appears that FCP1 and MEP50 co-sediment
in complexes of the same size (fractions 5±6).
Finally, using commercially available anti-PMRT5, a
component of the 20S methylosome complex, we did not
detect any speci®c association between FCP1 and PMRT5
(data not shown). Collectively, our data suggest that MEP50
and FCP1 associate into the nucleus and analysis of nuclear
protein distribution indicate that they co-sediment in a
complex of the same size distinct from the 20S methylosome
complex.
FCP1 interacts with spliceosomal snRNPs
The association of the FCP1 protein with MEP50, a
component of the methylosome complex, which binds to the
snRNP Sm proteins, raised the possibility that FCP1 might
interact with pre-mRNA spliceosomal snRNPs. It has been
suggested that, because MEP50 contains six WD repeats, it
can provide a platform for multiple protein interactions (16).
To determine whether FCP1 might interact in vivo with pre-
mRNA snRNPs complexes, FLAG-tagged FCP1 immuno-
af®nity materials from HFFCP1 nuclear extracts were assayed
for the presence of speci®c components of the snRNPs by
western blotting using antibodies against the snRNP proteins
U1 70 K and the common Sm protein B and B¢. The results
(Fig. 4A) show that the FCP1 protein co-immunoprecipitates
endogenous SmB and U1 SnRNP 70 proteins. The results
support the ®nding that FCP1 is able to interact with
components of the pre-mRNA machinery.
Given the association between FCP1 and components of the
snRNP we sought to investigate if FCP1 co-immunoprecipi-
tates the U1 snRNA, a common core element of snRNPs.
Nuclear extracts from the HFFCP1 cells and from the parental
cell line H1299 were prepared in the presence of RNase
inhibitor and immunoprecipitated with anti-FLAG M2 beads.
The immunoprecipitated extracts were run on SDS±PAGE and
transferred on Hybond N+ to perform northern blot with the
U1 snRNA probe. In parallel, the same extracts were analyzed
by western blot for the presence of U1 70 K and SmB (data not
shown). The results (Fig. 4B) show the presence of the
spliceosomal U1 RNA in the FLAG-immunoprecipitated
extracts. The presence of U1 RNA in the extracts was not
due to an unspeci®c binding to small RNAs as shown by the
lack of signal in northern-blotting with the 7SK RNA probe.
Collectively, these ®ndings suggest that FCP1 speci®cally
interacts in vivo with the pre-mRNA snRNP.
DISCUSSION
In this study we used an af®nity puri®cation assay to isolate
human FCP1 interacting partners. We demonstrated that, in
addition to RAP74, the FCP1-af®nity materials contained the
RNAPII, suggesting the presence of the FCP1/TFIIF/RNAPII
complex in vivo. Our data are in agreement with recent
puri®cation of a similar complex FCP1/TFIIF/PolII from
S.pombe (21). Our data suggest that FCP1 interacts with both
RNAPIIo and RNAPIIa forms. The association of FCP1 with
the hypophosphorylated RNAPII is consistent with the
previous ®ndings showing that FCP1 is a component of the
mammalian RNAPII holoenzyme (8). Likely, the association
of FCP1 with RNAPII that is not engaged in transcription may
prevent phosphorylation of the CTD by CTD-kinases. On the
Figure 3. Subcellular localization of MEP50. (A) HFFCP1 cell fractionation
(C, cytoplasmic fraction; N, nuclear fraction) were resolved by SDS±PAGE.
Extracts were analyzed by western blotting with anti MEP50 and FLAG and
subsequently the same extracts were probed with anti-Myc and anti-tubulin
a antibodies as control of the purity and the integrity of nuclear and
cytoplasmic protein fractions respectively. (B) MEP50 localize in both
nuclear and cytoplasm sub-cellular compartments. An example of immuno-
¯uorescence microscopy of human BJ1 cells using MEP50 antibody
is reported. DAPI nuclear staining of the same cells is shown.
(C) Fractionation of an H1299 cell extract (W, whole cell extract, N,
nuclear extract) by ultracentrifugation on a glycerol gradient. Distribution of
MEP50 and FCP1 in the gradient fractions and pellet (P) was monitored by
western blot using speci®c antibodies.
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other hand, it has been recently shown that a transcription-
independent CTD dephosphorylation occurs in X.laevis,
suggesting that free hyperphosphorylated RNAPII is a bona
®de substrate for FCP1 activity (12). Finally, it has recently
shown that FCP1 is associated with polymerase during
transcription elongation in vivo (15). Thus, it appears that
FCP1 has the inherent ability to interact with RNAPII
irrespectively from the CTD-phosphorylation status.
By mass spectrometry of af®nity puri®ed FCP1-associated
factors, we identi®ed a novel FCP1-interacting protein, named
MEP50. MEP50, together with PMRT5 and pICln, constitutes
the 20S methylosome complex, which is responsible for
diarginine methylation of the Sm protein and it is required for
snRNPs assembly. FCP1 co-immunoprecipitation analysis
supported the speci®c interaction between FCP1 and MEP50.
We demonstrate that FCP1 and MEP50 complex is present
into the nucleus, thus it represents a distinct entity from the
20S methylosome. Moreover, we did not detect any speci®c
association between FCP1 and the dimethylarginine PMRT5
component of the 20S methylosome. Conversely, we found
evidence that FCP1 interacts with Sm proteins, common
components of the snRNPs. Because MEP50 binds the Sm
proteins, we hypothesize that association between FCP1 and
Sm protein might be mediated by MEP50. It has been
suggested (16,22) that the WD repeat protein MEP50 may
provide a platform for multiple protein interactions. However,
because FCP1 associates with RNAPII and RNAPII has been
recently reported to associate the spliceosome complex (23), it
is conceivable if not likely, that interaction between FCP1 and
common components of the spliceosome complex might be
mediated by RNAPII. Moreover, we found no evidence of
speci®c association between MEP50 and RNAPII by
immunoprecipitation experiments (data not shown).
Other mammalian protein phosphatases have been de-
scribed to have a role in pre-mRNA splicing (24 and
references therein). Even if there is currently only limited
information on the spliceosomal substrates of these protein
phosphatases it is known that several splicing factors as the
SF2/ASF and SAP155 undergo phosphorylation/dephos-
phorylation events during the process of splicing (25±27). In
contrast with other phosphatase, FCP1 is the ®rst example of a
phosphatase that is involved in transcription elongation.
Our ®ndings add further support to the concept that there is
functional intercommunication between the transcription and
splicing machineries, and the RNAPII-CTD appears to play a
pivotal role in coordinating transcription and pre-RNA
processing (13 and references therein). Splicing factors have
been detected in association with a transcriptionally active
`holoenzyme' containing polymerase. Furthermore, the evi-
dence for reciprocal stimulation between splicing and tran-
scription machineries has been reported (28). The TAT-SF1
protein, able to interact with the P-TEFb CTD kinase, was
shown to bind speci®cally splicing factors and this association
positively in¯uences transcription (28). Interestingly, another
snRNA, the 7SK RNA, was shown to associate with the
P-TEFb complex and negatively modulates transcription
(19,29). Using the in vivo cross-linking/chromatin immuno-
precipitation assays it has been shown that FCP1 phosphatase
cross-links to promoter and coding regions, suggesting that the
FCP1 is associated with the elongating polymerase. Moreover,
mutations in the FCP1 lead to increase levels of CTD-Ser2
phosphorylation (15). Thus, it appears that FCP1 may regulate
transcription elongation by modulating the levels of CTD-
Ser2 phosphorylation. The ability of FCP1 to associate and to
dephosphorylate the RNAPII CTD at speci®c stage of
transcription elongation, and to interact in vivo with MEP50,
a protein associated with the common Sm factors, suggests the
possibility that FCP1 might play a regulatory role in the
coordination of transcription elongation and pre-mRNA
splicing process. Alternatively, association between FCP1
and MEP50 might lead to de-phosphorylation of MEP50 or
other components associated to MEP50. Clearly, additional
studies are required to elucidate the functional signi®cance of
this association.
ACKNOWLEDGEMENTS
We thank Dr Dreyfuss for gift of MEP50 antibody. This work
was supported by grants from the Italian Association for
Cancer Research (AIRC), Istituto Superiore di SanitaÁ,
Programma Nazionale di Ricerca AIDS and MURST
(COFIN).
REFERENCES
1. Conaway,J.W., Shilatifard,A., Dvir,A. and Conaway,R.C. (2000) Control
of elongation by RNA polymerase II. Trends Biochem. Sci., 25, 375±380.
2. Hengartner,C.J., Myer,V.E., Liao,S.M., Wilson,C.J., Koh,S.S. and
Young,R.A. (1998) Temporal regulation of RNA polymerase II by Srb10
and Kin28 cyclin-dependent kinases. Mol. Cell, 2, 43±53.
3. Sun,X., Zhang,Y., Cho,H., Rickert,P., Lees,E., Lane,W. and Reinberg,D.
(1998) NAT, a human complex containing Srb polypeptides that
Figure 4. (A) Nuclear extracts of HFFCP1 cells (NE, nuclear extracts; IP, FLAG-af®nity materials) were assayed by western blots using the indicated
antibodies. (B) Northern blots of nuclear extracts (NE) and the relative FLAG-af®nity materials (IP) from HFFCP1 cells were hybridized with the indicated
probes.
1004 Nucleic Acids Research, 2003, Vol. 31, No. 3
functions as a negative regulator of activated transcription. Mol. Cell, 2,
213±222.
4. Gu,W., Malik,S., Ito,M., Yuan,C.X., Fondell,J.D., Zhang,X.,
Martinez,E., Qin,J. and Roeder,R.G. (1999) A novel human SRB/MED-
containing cofactor complex, SMCC, involved in transcription
regulation. Mol. Cell, 3, 97±108.
5. Lee,T.I. and Young,R.A. (2000) Transcription of eukaryotic protein-
coding genes. Annu. Rev. Genet., 34, 77±137.
6. Price,D.H. (2000) P-TEFb, a cyclin-dependent kinase controlling
elongation by RNA polymerase II. Mol. Cell. Biol., 20, 2629±2634.
7. Archambault,J., Chambers,R.S., Kobor,M.S., Ho,Y., Cartier,M.,
Bolotin,D. Andrews,B., Kane,C.M. and Greenblatt,J. (1997) An essential
component of a C-terminal domain phosphatase that interacts with
transcription factor TFIIF in Saccharomyces cerevisiae. Proc. Natl Acad.
Sci. USA, 94, 14300±14305.
8. Archambault,J., Pan,G., Dahmus,G.K., Cartier,M., Marshall,N.,
Zhang,S., Dahmus,M.E. and Greenblatt,J. (1998)FCP1,the RAP74-
interacting subunit of a human protein phosphatase that dephosphorylates
the carboxyl-terminal domain of RNA polymerase IIO. J. Biol. Chem.,
273, 27593±27601.
9. Kobor,M.S., Archambault,J., Lester,W., Holstege,F.C., Gileadi,O.,
Jansma,D.B., Jennings,E.G., Kouyoumdjian,F., Davidson,A.R.,
Young,R.A. and Greenblatt,J. (1999) An unusual eukaryotic protein
phosphatase required for transcription by RNA polymerase II and CTD
dephosphorylation in S.cerevisiae. Mol. Cell, 4, 55±62.
10. Kobor,M.S., Simon,L.D., Omichinski,J., Zhong,G., Archambault,J. and
Greenblatt,J. (2000) A motif shared by TFIIF and TFIIB mediates their
interaction with RNA Polymerase II carboxy-terminal domain
phosphatase FCP1 in Saccharomyces cerevisiae. Mol. Cell. Biol., 20,
7438±7449.
11. Cho,H., Kim,T.K., Mancebo,H., Lane,W.S., Flores,O. and Reinberg,D.
(1999) A protein phosphatase functions to recycle RNA polymerase II.
Genes Dev., 13, 1540±1552.
12. Palancade,B., Dubois,M.F., Dahmus,M.E. and Bensaude,O. (2001)
Transcription-independent RNA polymerase II dephosphorylation by the
FCP1 carboxy-terminal domain phosphatase in Xenopus laevis early
embryos. Mol. Cell. Biol., 21, 6359±6368.
13. Maniatis,T. and Reed,R. (2002) An extensive network of coupling among
gene expression machines. Nature, 416, 499±506.
14. Komarnitsky,P., Cho,E.J. and Buratowski,S. (2000) Different
phosphorylated forms of RNA polymerase II and associated mRNA
processing factors during transcription. Genes Dev., 14, 2452±2460.
15. Cho,E.J., Kobor,M.S., Kim,M., Greenblatt,J. and Buratowski,S. (2001)
Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser2 of the
RNA polymerase IIC-terminal domain. Genes Dev., 15, 3319±3329.
16. Friesen,W.J., Wyce,A., Paushkin,S., Abel,L., Rappsilber,J., Mann,M. and
Dreyfuss,G. (2002) A novel WD repeat protein component of the
methylosome binds Sm proteins. J. Biol. Chem., 277, 8243±8247.
17. Licciardo,P., Ruggiero,L., Lania,L. and Majello,B. (2001) Transcription
activation by targeted recruitment of the RNA polymerase II CTD
phosphatase FCP1. Nucleic Acids Res., 29, 3539±3545.
18. Napolitano,G., Licciardo,P., Carbone,R., Majello,B. and Lania,L. (2002)
CDK9 has the intrinsic property to shuttle between nucleus and
cytoplasm and enhanced expression of cyclin T1promotes its nuclear
localization. J. Cell Physiol., 192, 209±215.
19. Nguyen,V.T., Kiss,T., Michels,A.A. and Bensaude,O. (2001) 7SK small
nuclear RNA binds to and inhibits the activity of CDK9/cyclin T
complexes. Nature, 414, 322±325.
20. Chambers,R.S., Wang,B.Q., Burton,Z.F. and Dahmus,M.E. (1995) The
activity of COOH-terminal domain phosphatase is regulated by a docking
site on RNA polymerase II and by the general transcription factors IIF
and IIB. J. Biol. Chem., 270, 14962±14969.
21. Kimura,M., Suzuki,H. and Ishihama,A. (2002) Formation of a carboxy-
terminal domain phosphatase (Fcp1)/TFIIF/RNA polymerase II (polII)
complex in Schizosaccharomyces pombe involves direct interaction
between Fcp1 and the Rpb4 subunit of polII. Mol. Cell. Biol., 22,
1577±1588.
22. Paushkin,S., Gubitz,A.K., Massenet,S. and Dreyfuss,G. (2002) The SMN
complex, an assemblyosome of ribonucleoproteins. Curr. Opin. Cell
Biol., 14, 305±312.
23. Robert,F., Blanchette,M., Maes,O., Chabot,B. and Coulombe,F. (2002) A
human RNA polymerase II-containing complex associated with factors
necessary for spliceosome assembly. J. Biol. Chem., 277, 9302±9306.
24. Bollen,M. and Beullens,M. (2002) Signaling by protein phosphatases in
the nucleus. Trends Cell Biol., 12, 138±145.
25. Wang,X., Bruderer,S., Ra®,Z., Xue,J., Milburn,P.J., Kramer,A. and
Robinson,P.J. (1999) Phosphorylation of splicing factor SF1 on Ser20 by
cGMP-dependent protein kinase regulates spliceosome assembly.
EMBO J., 18, 4549±4559.
26. Xiao,S.-H. and Manley,J.L. (1998) Phosphorylation-dephosphorylation
differentially affects activities of splicing factor ASF/SF2. EMBO J., 17,
6359±6367.
27. Wang,C., Chua,K., Seghezzi,W., Lee,E., Gozani,O. and Reed,R. (1998)
Phosphorylation of spliceosomal protein SAP 155 coupled with splicing
catalysis. Genes Dev., 12, 1409±1414.
28. Fong,Y.W. and Zhou,Q. (2001) Stimulatory effect of splicing factors on
transcriptional elongation. Nature, 414, 929±933.
29. Yang,Z., Zhu,Q., Luo,K. and Zhou,Q. (2001) The 7SK small nuclear
RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature,
414, 317±322.
Nucleic Acids Research, 2003, Vol. 31, No. 3 1005
